Melanoma Therapeutics Market to 2020 - Market Growth - PowerPoint PPT Presentation

View by Category
About This Presentation
Title:

Melanoma Therapeutics Market to 2020 - Market Growth

Description:

GBI Research, a leading business intelligence provider, has released its latest research report, "Melanoma Therapeutics Market to 2020 - Rising Prevalence and Evolving Treatment Algorithms to Drive Market Growth” Melanoma is a highly heterogeneous disease comprising Cutaneous Melanoma (CM), Ocular Melanoma (OM), Mucosal Melanoma (MM), melanoma of the internal organs, and, according to some classifications, melanoma of the soft parts (non-bony and non-cartilaginous tissues) of the body. CM is by far the most common form of melanoma, accounting for approximately 90–95% of all melanomas. Get more about this report at: – PowerPoint PPT presentation

Number of Views:57

less

Write a Comment
User Comments (0)
Transcript and Presenter's Notes

Title: Melanoma Therapeutics Market to 2020 - Market Growth


1
Melanoma Therapeutics Market to 2020 - Rising
Prevalence and Evolving Treatment Algorithms to
Drive Market Growth
2
Summary
 
GBI Research, a leading business intelligence
provider, has released its latest research
report, "Melanoma Therapeutics Market to 2020 -
Rising Prevalence and Evolving Treatment
Algorithms to Drive Market Growth Melanoma is a
highly heterogeneous disease comprising Cutaneous
Melanoma (CM), Ocular Melanoma (OM), Mucosal
Melanoma (MM), melanoma of the internal organs,
and, according to some classifications, melanoma
of the soft parts (non-bony and non-cartilaginous
tissues) of the body. CM is by far the most
common form of melanoma, accounting for
approximately 9095 of all melanomas. Get more
about this report at http//www.bigmarketresearch
.com/melanoma-therapeutics-to-2020-rising-prevalen
ce-and-evolving-treatment-algorithms-to-drive-grow
th-market
3
Summary
 
Historically, melanoma has been considered as a
very challenging disease to treat with
pharmacotherapy. However, in recent years,
understanding of the pathophysiology and
heterogeneity of melanoma, and particularly CM,
has developed considerably. This has led to the
approval of several new drug agents indicated for
CM since 2011, namely Sylatron (peginterferon
alfa-2b), Yervoy (ipilimumab), Opdivo,
(nivolumab), Keytruda (pembrolizumab), Zelboraf
(vemurafenib), Tafinlar (dabrafenib) and Mekinist
(trametinib). These drugs have dramatically
improved the treatment options for CM patients,
leading to unprecedented market growth. Rapid
market growth is also anticipated over the
forecast period due to the expanding melanoma
treatment population and the continued uptake of
recently approved drugs. The melanoma pipeline is
currently strong, with several promising
molecules in development including, Polynomas
seviprotimut-L, Amgens talimogene laherparepvec
(T-VEC) and Roche and Genentechs cobimetinib in
combination with Zelboraf, which are in
development for CM, as well as AstraZenecas
selumetinib which is in development for OM.
Consequently, the melanoma therapeutics market is
projected to grow from 1.3 billion in 2013 to
3.6 billion in 2020, at a CAGR of 15.4.
4
Scope
 
  • The report analyzes treatment usage patterns,
    drug types available and pipeline and market
    forecasts across indications for melanoma.The
    report covers and includes -
  • An introduction to the melanoma indication,
    including disease symptoms, epidemiology,
    etiology, pathophysiology, staging, diagnosis and
    treatment.
  • In-depth analysis of the current melanoma
    marketed products landscape including product
    profiles of the main drugs used in melanoma and
    heat maps that compare safety and efficacy
    parameters of the various drugs.
  • Comprehensive analysis of the melanoma pipeline
    by phase of development, molecule type, molecular
    target and novelty. A comparative analysis of
    late-stage pipeline drugs that are likely to
    enter the market in the forecast period is also
    provided alongside heat maps.
  • Additional in-depth analysis of melanoma clinical
    trials by size, duration, failure rates and
    primary and secondary endpoints.
  • To Get More Details Enquire _at_ http//www.bigmarket
    research.com/report-enquiry/159539

5
Table Of Content
1 Table of Contents 2 Introduction 11 3
Marketed Products 49 4 Melanoma Pipeline 68 5
Market Forecast to 2020 117 6 Strategic
Consolidations 135 7 Appendix 147
6
Reason to buy
  • The report will assist business development and
    enable marketing executives to strategize their
    product launches, by allowing them to
  • Gain a comprehensive understanding of the
    melanoma indication including segmentation of
    disease and treatment algorithms.
  • Understand the current melanoma marketed products
    landscape and recognize the dominant therapeutic
    agents and pharmaceutical players involved.
  • Identify trends and developments within the
    melanoma pipeline including which molecule types
    and molecular targets are prominent.
  • Consider market opportunities and potential risks
    by examining trends in melanoma clinical trial
    duration and size, as well as clinical trial
    failure rates, amongst clinical trial Phases and
    molecule types.
  • Assess the potential clinical and commercial
    impact of current late-stage pipeline molecules
    on the melanoma therapeutics market.

7
FOR MORE DETAILS
Visit us at
http//www.bigmarketresearch.com/melanoma-therapeu
tics-to-2020-rising-prevalence-and-evolving-treatm
ent-algorithms-to-drive-growth-market
Stay With Us
5933 NE Win Sivers Drive,205, Portland, OR
97220United States
TELEPHONE 1 (855) 711-1555E-MAIL
sales_at_bigmarketresearch.com
About PowerShow.com